411 related articles for article (PubMed ID: 1655118)
1. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
Beck WT; Danks MK
Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
[TBL] [Abstract][Full Text] [Related]
2. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
Holm C; Covey JM; Kerrigan D; Pommier Y
Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
[TBL] [Abstract][Full Text] [Related]
3. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
4. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
5. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G
Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
Utsugi T; Mattern MR; Mirabelli CK; Hanna N
Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance.
Liu LF; D'Arpa P
Important Adv Oncol; 1992; ():79-89. PubMed ID: 1316311
[No Abstract] [Full Text] [Related]
9. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.
Gupta RS; Gupta R; Eng B; Lock RB; Ross WE; Hertzberg RP; Caranfa MJ; Johnson RK
Cancer Res; 1988 Nov; 48(22):6404-10. PubMed ID: 2846151
[TBL] [Abstract][Full Text] [Related]
10. Fluorometric assays for DNA topoisomerases and topoisomerase-targeted drugs: quantitation of catalytic activity and DNA cleavage.
Andrea JE; Adachi K; Morgan AR
Mol Pharmacol; 1991 Oct; 40(4):495-501. PubMed ID: 1656189
[TBL] [Abstract][Full Text] [Related]
11. DNA topoisomerase II mutations and resistance to anti-tumor drugs.
Vassetzky YS; Alghisi GC; Gasser SM
Bioessays; 1995 Sep; 17(9):767-74. PubMed ID: 8763829
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells.
Mattern MR; Tan KB; Zimmerman JP; Mong SM; Bartus JO; Hofmann GA; Drake FH; Johnson RK; Crooke ST; Mirabelli CK
Anticancer Drug Des; 1989 Aug; 4(2):107-24. PubMed ID: 2478139
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
Haldane A; Finlay GJ; Baguley BC
Oncol Res; 1993; 5(3):133-8. PubMed ID: 8260750
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity.
Utsugi T; Demuth S; Hanna N
Cancer Res; 1989 Mar; 49(6):1429-33. PubMed ID: 2538225
[TBL] [Abstract][Full Text] [Related]
16. [Inhibitors of DNA topoisomerases].
Andoh T
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151
[TBL] [Abstract][Full Text] [Related]
17. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK
Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903
[TBL] [Abstract][Full Text] [Related]
18. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
19. [Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors].
Ishida R; Andoh T
Gan To Kagaku Ryoho; 1994 Jun; 21(7):952-61. PubMed ID: 8002633
[TBL] [Abstract][Full Text] [Related]
20. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells.
de Tinguy-Moreaud E; Pourquier P; Montaudon D; Robert J
Anticancer Res; 1994; 14(1A):99-103. PubMed ID: 8166463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]